Pharma Mar SA (PHMMF)
94.60
0.00 (0.00%)
USD |
OTCM |
Sep 25, 16:00
Pharma Mar Research and Development Expense (TTM) : 110.74M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 110.74M |
| March 31, 2026 | 109.74M |
| December 31, 2025 | 107.73M |
| September 30, 2025 | 107.30M |
| June 30, 2025 | 108.58M |
| March 31, 2025 | 104.83M |
| December 31, 2024 | 111.94M |
| September 30, 2024 | 113.75M |
| June 30, 2024 | 112.35M |
| March 31, 2024 | 114.29M |
| December 31, 2023 | 107.36M |
| September 30, 2023 | 103.10M |
| June 30, 2023 | 99.99M |
| March 31, 2023 | 93.49M |
| December 31, 2022 | 100.44M |
| June 30, 2022 | 95.36M |
| March 31, 2022 | 89.84M |
| December 31, 2021 | 86.20M |
| September 30, 2021 | 74.14M |
| June 30, 2021 | 69.70M |
| March 31, 2021 | 63.99M |
| December 31, 2020 | 59.82M |
| September 30, 2020 | 51.44M |
| June 30, 2020 | 47.81M |
| March 31, 2020 | 49.45M |
| Date | Value |
|---|---|
| December 31, 2019 | 52.07M |
| September 30, 2019 | 62.26M |
| June 30, 2019 | 67.69M |
| March 31, 2019 | 79.03M |
| December 31, 2018 | 87.34M |
| September 30, 2018 | 94.98M |
| June 30, 2018 | 97.82M |
| March 31, 2018 | 94.39M |
| December 31, 2017 | 88.98M |
| September 30, 2017 | 84.70M |
| June 30, 2017 | 83.55M |
| March 31, 2017 | 85.11M |
| December 31, 2016 | 86.72M |
| September 30, 2016 | 82.97M |
| June 30, 2016 | 78.86M |
| March 31, 2016 | 73.23M |
| December 31, 2015 | 66.80M |
| September 30, 2015 | 67.09M |
| June 30, 2015 | 67.94M |
| March 31, 2015 | 68.10M |
| December 31, 2014 | 69.43M |
| September 30, 2014 | 65.01M |
| June 30, 2014 | 60.88M |
| March 31, 2014 | 57.93M |
| December 31, 2013 | 56.73M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Oryzon Genomics SA | 20.67M |
| Grifols SA | 477.82M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alkermes Plc | 384.84M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |